Bullous systemic lupus erythematosus (BSLE) is extremely rare but distinct disease, characterized by vesicobullous skin eruptions in systemic lupus erythematosus (SLE). It can develop either before or after a diagnosis of SLE has been established. BSLE is characterized by a dermatitis herpetiformis-like histology and an autoimmunity to type VII collagen. It must be differentiated from other autoimmune vesicobullous diseases such as epidermolysis bullosa acquisita, dermatitis herpetiformis, linear IgA disease, and bullous pemphigoid. Its important to combine clinical, histological, and immunofluorescence findings to establish a diagnosis of BSLE. We report a case of BSLE to illustrate and emphasize the need for an integrative diagnostic approach.
Immunofluorescence with salt slit skin smear was not done due to unavailability. As initial therapy we maintained adequate hydration followed by high dose Prednisolone (80mg/day), Hydroxychloroquine (400 mg/day), Azathioprine (100 mg/day). As blister appeared persistently we add Dapsone (50mg/day) that made striking response.
Discussion:
In 1973, Pedro and Dahl 3 described the first case of BSLE. After this, several cases with similar characteristics were reported. BSLE patients produce autoantibodies that recognize type VII collagen, a major component of anchoring fibrils, which play an important role in dermo-epidermal adhesion. Chan and colleagues 4 identified further autoantibodies reacting to multiple basement membrane components including bullous pemphigoid antigen 1, laminin-5 and laminin-6 in patients with BSLE. This hyper-immune state seems to be associated with the gene for major histocompatibility complex HLA-DR2. 3 Patients with SLE rarely (in less than 1%) develop widespread vesicobullous eruptions that cannot be classified as either of the primary bullous dermatoses and are not merely a manifestation of extreme basal cell hydropic degeneration and the resulting epidermal-dermal separation. In such cases, it is referred to as BSLE, a unique dermatosis that is regarded as a distinct variant of SLE. [5] [6] [7] Similarly to SLE, BSLE most often affects young patients, predominantly female, in the second to fourth decades of life. Although any sun-exposed or non-sunexposed areas can be affected, the upper trunk, neck, supraclavicular areas, and proximal extremities are predilection sites. 5, 6 The skin eruption comprises bullae arising either from areas affected by diffuse erythema or on an urticarial base resembling bullous pemphigoid, or as grouped vesicular lesions mimicking dermatitis herpetiformis. 6, 7 The onset of vesicobullous cutaneous lesions can precede, coincide with, or follow the diagnosis of SLE, as defined by the revised American Rheumatism Association criteria for classification of SLE. 3 
Conclusion:
BSLE responds well to treatment with Dapsone, which differs from EBA. In cases that do not respond to Dapsone, the use of Prednisone and Azathioprine is suggested. BSLE may regress completely and independently of systemic involvement without recurrence.
